Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ABEONA THERAPEUTICS INC.ABEO · Entity 5808 | Chief Executive Officer | March 29, 2018 | April 03, 2018 |
| ALEXION PHARMACEUTICALS, INC.ALXN · Entity 137086 | EVP, Chief Commercial Officer | February 28, 2017 | March 06, 2017 |
| Karyopharm Therapeutics Inc.KPTI · Entity 781 | Director | August 31, 2018 | September 04, 2018 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ABEONA THERAPEUTICS INC.
Report date March 29, 2018 · Filed April 03, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.65 · Expires 2028-03-29 | Direct | 87,500 |
Reported balance
After 2018-03-29 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2018-03-29 · Grant · Acquired 87,500 · Balance 87,500 F1: 100% accelerated vesting on change of control |
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.65 · Expires 2028-03-29 | Direct | 262,500 |
Reported balance
After 2018-03-29 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2018-03-29 · Grant · Acquired 262,500 · Balance 262,500 F1: 100% accelerated vesting on change of control F2: After twelve months from the Grant Date options vest 2.0833% monthly. All options vested 48 months from Grant Date. |
Filing footnotes · ownership attribution and instrument terms
F1: 100% accelerated vesting on change of control
F2: After twelve months from the Grant Date options vest 2.0833% monthly. All options vested 48 months from Grant Date.
ALEXION PHARMACEUTICALS, INC.
Report date February 28, 2017 · Filed March 06, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, par value $.0001 per shareSEC Table I · non-derivative | Direct | 33,860 |
Reported balance
After 2017-02-28 transaction · row 1
1 source rowRow 1 · 2017-02-28 · Sale · Disposed 3,783 · Balance 33,860 F1: The transaction is made pursuant to the terms of a sales plan designed to meet the requirements of Rule 10b5-1(c)(1) of the Securities Exchange Act. F2: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $130.70 - $131.69. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares sold at each price. |
Filing footnotes · ownership attribution and instrument terms
F1: The transaction is made pursuant to the terms of a sales plan designed to meet the requirements of Rule 10b5-1(c)(1) of the Securities Exchange Act.
F2: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $130.70 - $131.69. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares sold at each price.
Karyopharm Therapeutics Inc.
Report date August 31, 2018 · Filed September 04, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Nonstatutory stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $21.05 · Expires 2028-08-30 | Direct | 34,000 |
Reported balance
After 2018-08-31 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2018-08-31 · Grant · Acquired 34,000 · Balance 34,000 F1: This option was granted on August 31, 2018. The shares underlying this option vest as to one-third (1/3) of the shares on August 31, 2019 and as to the remaining two-thirds (2/3) of the shares in 24 equal monthly installments thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: This option was granted on August 31, 2018. The shares underlying this option vest as to one-third (1/3) of the shares on August 31, 2019 and as to the remaining two-thirds (2/3) of the shares in 24 equal monthly installments thereafter.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 31, 2018 Filed Sep 4, 2018 20:38 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | GrantNonstatutory stock option (right to buy) · Derivative | 34,000 | $0.00 Strike: $21.05 | $0.00 |
DisclosureSEC source: 0001209191-18-049208 · doc4.xml · derivative · entry 1 Thiel Carsten · CIK 0001633582 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,000 Underlying: Common Stock · 34,000 shares Expires 2028-08-30 F1 · derivative.exercise_date: This option was granted on August 31, 2018. The shares underlying this option vest as to one-third (1/3) of the shares on August 31, 2019 and as to the remaining two-thirds (2/3) of the shares in 24 equal monthly installments thereafter. Read SEC document |
| March 29, 2018 Filed Apr 3, 2018 00:35 UTC | ABEONA THERAPEUTICS INC. ABEO · Entity 5808 | GrantStock option (right to buy) · Derivative | 262,500 | $0.00 Strike: $13.65 | $0.00 |
DisclosureSEC source: 0000318306-18-000002 · primary_doc.xml · derivative · entry 2 Thiel Carsten · CIK 0001633582 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 262,500 Underlying: Common stock · 262,500 shares Expires 2028-03-29 F1 · shares: 100% accelerated vesting on change of control F2 · derivative.exercise_date: After twelve months from the Grant Date options vest 2.0833% monthly. All options vested 48 months from Grant Date. Read SEC document |
| March 29, 2018 Filed Apr 3, 2018 00:35 UTC | ABEONA THERAPEUTICS INC. ABEO · Entity 5808 | GrantStock option (right to buy) · Derivative | 87,500 | $0.00 Strike: $13.65 | $0.00 |
DisclosureSEC source: 0000318306-18-000002 · primary_doc.xml · derivative · entry 1 Thiel Carsten · CIK 0001633582 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,500 Underlying: Common stock · 87,500 shares Expires 2028-03-29 F1 · shares: 100% accelerated vesting on change of control Read SEC document |
| February 28, 2017 Filed Mar 1, 2017 19:45 UTC | ALEXION PHARMACEUTICALS, INC. ALXN · Entity 137086 | GrantOption to Purchase Common Stock · Derivative | 14,800 | $0.00 Strike: $131.25 | $0.00 |
DisclosureSEC source: 0000899866-17-000056 · wf-form4_148841549780217.xml · derivative · entry 4 Thiel Carsten · CIK 0001633582 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,600 Underlying: Common Stock, par value $.0001 per share · 14,800 shares Expires 2027-02-28 F4 · shares: Stock option award under 2004 Incentive Plan. 25% vest on the first anniversary of the grant date, 1/16 every three months thereafter until fully vested over 4 years. Read SEC document |
| February 28, 2017 Filed Mar 1, 2017 19:45 UTC | ALEXION PHARMACEUTICALS, INC. ALXN · Entity 137086 | GrantCommon Stock, par value $.0001 per share | 7,500 | $0.00 | $0.00 |
DisclosureSEC source: 0000899866-17-000056 · wf-form4_148841549780217.xml · nonDerivative · entry 3 Thiel Carsten · CIK 0001633582 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,643 F3 · shares: Award of Restricted Stock Units under the 2004 Incentive Plan. 25% vests on each anniversary of the grant date. Read SEC document |
| February 28, 2017 Filed Mar 1, 2017 19:45 UTC | ALEXION PHARMACEUTICALS, INC. ALXN · Entity 137086 | SaleCommon Stock, par value $.0001 per share | 54 | $0.00 | $0.00 |
DisclosureSEC source: 0000899866-17-000056 · wf-form4_148841549780217.xml · nonDerivative · entry 2 Thiel Carsten · CIK 0001633582 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,143 F1 · shares: This sale was made to cover withholding taxes immediately following the vesting of previously granted Restricted Stock Units. F2 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $131.00 - $131.99. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares sold at each price. Read SEC document |
| February 28, 2017 Filed Mar 6, 2017 18:03 UTC | ALEXION PHARMACEUTICALS, INC. ALXN · Entity 137086 | SaleCommon Stock, par value $.0001 per share | 3,783 | $131.01 | $495,610.83 |
DisclosureSEC source: 0000899866-17-000067 · wf-form4_148884141474383.xml · nonDerivative · entry 1 Thiel Carsten · CIK 0001633582 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,860 F1 · shares: The transaction is made pursuant to the terms of a sales plan designed to meet the requirements of Rule 10b5-1(c)(1) of the Securities Exchange Act. F2 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $130.70 - $131.69. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares sold at each price. Read SEC document |
| February 27, 2017 Filed Mar 1, 2017 19:45 UTC | ALEXION PHARMACEUTICALS, INC. ALXN · Entity 137086 | SaleCommon Stock, par value $.0001 per share | 71 | $131.20 | $9,315.20 |
DisclosureSEC source: 0000899866-17-000056 · wf-form4_148841549780217.xml · nonDerivative · entry 1 Thiel Carsten · CIK 0001633582 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,197 F1 · shares: This sale was made to cover withholding taxes immediately following the vesting of previously granted Restricted Stock Units. F2 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $131.00 - $131.99. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares sold at each price. Read SEC document |
| February 06, 2017 Filed Feb 8, 2017 16:39 UTC | ALEXION PHARMACEUTICALS, INC. ALXN · Entity 137086 | SaleCommon Stock, par value $.0001 per share | 165 | $125.69 | $20,738.85 |
DisclosureSEC source: 0000899866-17-000026 · wf-form4_148658995271085.xml · nonDerivative · entry 1 Thiel Carsten · CIK 0001633582 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,268 F1 · shares: This sale was made to cover withholding taxes immediately following the vesting of previously granted Performance Stock Units. F2 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $125.00 - $125.99. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares sold at each price. Read SEC document |
| December 09, 2016 Filed Dec 13, 2016 18:24 UTC | ALEXION PHARMACEUTICALS, INC. ALXN · Entity 137086 | SaleCommon Stock, par value $.0001 per share | 2,308 | $130.00 | $300,040.00 |
DisclosureSEC source: 0000899866-16-000393 · wf-form4_148167147614007.xml · nonDerivative · entry 1 Thiel Carsten · CIK 0001633582 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,433 F1 · shares: This transaction was made pursuant to the terms of a sales plan designed to meet the requirements of Rule 10b5-1(c)(1) of the Securities Exchange Act. Read SEC document |
| October 14, 2016 Filed Oct 18, 2016 18:29 UTC | ALEXION PHARMACEUTICALS, INC. ALXN · Entity 137086 | SaleCommon Stock, par value $.0001 per share | 4,584 | $120.28 | $551,363.52 |
DisclosureSEC source: 0000899866-16-000367 · wf-form4_147682978520075.xml · nonDerivative · entry 1 Thiel Carsten · CIK 0001633582 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,741 F1 · shares: The transactions reported by this Form 4 are made pursuant to the terms of a sales plan designed to meet the requirements of Rule 10b5-1(c)(1) of the Securities Exchange Act. Read SEC document |
| October 03, 2016 Filed Oct 5, 2016 17:25 UTC | ALEXION PHARMACEUTICALS, INC. ALXN · Entity 137086 | SaleCommon Stock, par value $.0001 per share | 29 | $122.41 | $3,549.89 |
DisclosureSEC source: 0000899866-16-000365 · wf-form4_147570274345182.xml · nonDerivative · entry 1 Thiel Carsten · CIK 0001633582 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,325 F1 · shares: This sale was made to cover withholding taxes immediately following the vesting of previously granted Restricted Stock Units. F2 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $122.00 - $122.99. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares sold at each price. Read SEC document |
| September 13, 2016 Filed Sep 14, 2016 16:34 UTC | ALEXION PHARMACEUTICALS, INC. ALXN · Entity 137086 | SaleCommon Stock, par value $.0001 per share | 3,000 | $129.00 | $387,000.00 |
DisclosureSEC source: 0000899866-16-000355 · wf-form4_147388523627173.xml · nonDerivative · entry 2 Thiel Carsten · CIK 0001633582 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,354 F3 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $129.00 - $129.99. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares sold at each price. Read SEC document |
| September 12, 2016 Filed Sep 14, 2016 16:34 UTC | ALEXION PHARMACEUTICALS, INC. ALXN · Entity 137086 | SaleCommon Stock, par value $.0001 per share | 225 | $124.20 | $27,945.00 |
DisclosureSEC source: 0000899866-16-000355 · wf-form4_147388523627173.xml · nonDerivative · entry 1 Thiel Carsten · CIK 0001633582 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,354 F1 · shares: This sale was made to cover withholding taxes immediately following the vesting of previously granted Restricted Stock Units. F2 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $124.00 - $124.99. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares sold at each price. Read SEC document |
| September 06, 2016 Filed Sep 8, 2016 16:33 UTC | ALEXION PHARMACEUTICALS, INC. ALXN · Entity 137086 | SaleCommon Stock, par value $.0001 per share | 1,000 | $125.94 | $125,940.00 |
DisclosureSEC source: 0000899866-16-000351 · wf-form4_147336677889789.xml · nonDerivative · entry 1 Thiel Carsten · CIK 0001633582 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,579 F1 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $125.00 - $125.99. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares sold at each price. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.